Phase 3 Recruiting Network
This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medicat…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT05929768
Sites in Washington: - Providence Regional Cancer System-Aberdeen — Aberdeen, Washington
- FHCC Overlake — Bellevue, Washington
- PeaceHealth Saint Joseph Medical Center — Bellingham, Washington
- Providence Regional Cancer System-Centralia — Centralia, Washington
- Swedish Cancer Institute-Edmonds — Edmonds, Washington
Phase 3 Recruiting Academic/Other
This phase III trial compares 6 months of human epidermal growth factor receptor 2 (HER2)-targeted therapy to 12 months of HER2-targeted therapy for the treatment of HER2-positive (+) breast cancer in patients that had a pathologic complet…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT06876714
Sites in Washington: - Swedish Cancer Institute-Edmonds — Edmonds, Washington
- Swedish Cancer Institute-Issaquah — Issaquah, Washington
- Skagit Regional Health Cancer Care Center — Mount Vernon, Washington
- Swedish Medical Center-First Hill — Seattle, Washington
- Saint Joseph Medical Center Hematology and Oncology - Silverdale — Silverdale, Washington
Phase 3 Recruiting Industry
The goal of this study is to find out if the experimental product, sacituzumab govitecan-hziy (SG) in combination with pembrolizumab given after surgery, is effective and safe compared to the treatment of physician's choice (TPC) which inc…
Sponsor: Gilead Sciences
NCT ID: NCT05633654
Sites in Washington: - Providence Regional Cancer System — Lacey, Washington
- MultiCare Regional Cancer Center - Tacoma — Puyallup, Washington
- Northwest Medical Specialties, PLLC — Puyallup, Washington
- University of Washington — Renton, Washington
- Medical Oncology Associates — Spokane, Washington
Phase 3 Recruiting Industry
The primary goal of this study is to evaluate the effectiveness of elacestrant versus standard endocrine therapy in participants with node-positive, Estrogen Receptor-positive (ER+), Human Epidermal Growth Factor-2 negative (HER2-) early b…
Sponsor: Stemline Therapeutics, Inc.
NCT ID: NCT06492616
Sites in Washington: - Vista Oncology — Olympia, Washington
- Virginia Mason Medical Center — Seattle, Washington
- Swedish Cancer Institute — Seattle, Washington
- Fred Hutchinson Cancer Center — Seattle, Washington
- Fred Hutch CC at UWMC-Northwest — Seattle, Washington
Phase 3 Recruiting Industry
This is a Phase III, randomised, open-label, 3-arm, multicentre, international study assessing the efficacy and safety of Dato-DXd with or without durvalumab compared with investigator's choice chemotherapy in combination with pembrolizuma…
Sponsor: AstraZeneca
NCT ID: NCT06103864
Sites in Washington: - Research Site — Tacoma, Washington
Phase 3 Recruiting Industry
This study will evaluate the efficacy and safety of the combination of inavolisib plus a cyclin-dependent kinase 4 and 6 inhibitor (CDK4/6i) and letrozole versus placebo plus a CDK4/6i and letrozole in the first-line setting in participant…
Sponsor: Hoffmann-La Roche
NCT ID: NCT06790693
Sites in Washington: - Swedish Cancer Institute - Edmonds Campus — Edmonds, Washington
- Providence Regional Cancer Partnership — Everett, Washington
- Swedish Cancer Institute - Issaquah — Seattle, Washington
- Swedish Cancer Institute — Seattle, Washington
- Northwest Medical Specialties — Tacoma, Washington
Phase 3 Recruiting Industry
The purpose of the study is to demonstrate superiority of Saruparib (AZD5305) relative to placebo added to a standard radiation therapy (RT) + androgen deprivation therapy (ADT) regimen by assessment of metastases-free survival in particip…
Sponsor: AstraZeneca
NCT ID: NCT06952803
Sites in Washington: - Research Site — Seattle, Washington
Phase 3 Recruiting Industry
This study will evaluate the efficacy and safety of inavolisib in combination with Phesgo (pertuzumab, trastuzumab, and rHuPH20 injection for subcutaneous use) compared with placebo in combination with Phesgo, as maintenance therapy, after…
Sponsor: Hoffmann-La Roche
NCT ID: NCT05894239
Sites in Washington: - Kadlec Clinic Hematology and Oncology — Kennewick, Washington
- Swedish Medical Center — Seattle, Washington
Phase 2 Recruiting NIH
This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients with solid tumors that have spread to nearby tissue or lymph nodes (locally adva…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05564377
Sites in Washington: - Swedish Cancer Institute-Edmonds — Edmonds, Washington
- Swedish Cancer Institute-Issaquah — Issaquah, Washington
- Providence Regional Cancer System-Lacey — Lacey, Washington
- Valley Medical Center — Renton, Washington
- Swedish Medical Center-First Hill — Seattle, Washington
Phase 1, Phase 2 Recruiting Industry
The purpose of this clinical study is to learn about the safety and effects of the study medicine (called disitamab vedotin) for the possible treatment of people with breast cancer that is hard to treat and has spread in the body (advanced…
Sponsor: Pfizer
NCT ID: NCT06966453
Sites in Washington: - Swedish Cancer Institute — Seattle, Washington
- Swedish Medical Center — Seattle, Washington
Phase 2 Recruiting Academic/Other
The purpose of this study is to further advance the ability to practice personalized medicine by learning which new drug agents are most effective with which types of breast cancer tumors and by learning more about which early indicators o…
Sponsor: QuantumLeap Healthcare Collaborative
NCT ID: NCT01042379
Sites in Washington: - Swedish Cancer Institute — Seattle, Washington
- University of Washington — Seattle, Washington
Phase 1, Phase 2 Recruiting Industry
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1303/BNT323 in subjects with advanced solid tumors that express HER2.
Sponsor: DualityBio Inc.
NCT ID: NCT05150691
Sites in Washington: - Swedish Cancer Institute — Seattle, Washington
Phase 2 Recruiting Industry
The purpose of this study is to see if zanidatamab is safe and effective, when combined with chemotherapy, in treating people who has Human Epidermal Growth Factor Receptor 2 (HER2)-positive, early-stage breast cancer
Sponsor: Jazz Pharmaceuticals
NCT ID: NCT07102381
Sites in Washington: - Northwest Medical Specialties — Puyallup, Washington
- Northwest Cancer Specialists — Vancouver, Washington
Phase 2 Recruiting Industry
This study is designed to assess the efficacy and safety of ifinatamab deruxtecan (I-DXD) in the following tumor types: endometrial cancer (EC); head and neck squamous cell carcinoma (HNSCC); pancreatic ductal adenocarcinoma (PDAC); colore…
Sponsor: Daiichi Sankyo
NCT ID: NCT06330064
Sites in Washington: - Wenatchee Hospitals and Clinics — Wenatchee, Washington
Phase 2 Recruiting Industry
This open-label research study is studying (Z)-endoxifen as a possible treatment for pre-menopausal women with ER+/HER2- breast cancer. (Z)-endoxifen belongs to a group of drugs called selective estrogen receptor modulators or "SERM", whic…
Sponsor: Atossa Therapeutics, Inc.
NCT ID: NCT05607004
Sites in Washington: - Fred Hutchinson Cancer Center — Seattle, Washington
Phase 1, Phase 2 Recruiting Industry
This is a two-part, open-label, multicenter, dose escalation and dose expansion study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and anti- tumor activity of ETX-19477, a novel reversible s…
Sponsor: 858 Therapeutics, Inc.
NCT ID: NCT06395519
Sites in Washington: - Fred Hutchinson Cancer Center — Seattle, Washington
Phase 1, Phase 2 Recruiting Industry
Phase I: Characterize safety and tolerability of ECI830 as a single agent and in combination with ribociclib and fulvestrant. Identify dose range for optimization/recommended dose for future studies. Phase II: Assess the anti-tumor activit…
Sponsor: Novartis Pharmaceuticals
NCT ID: NCT06726148
Sites in Washington: - Fred Hutch Cancer Research — Seattle, Washington
Phase 2 Recruiting Academic/Other
The usual approach to care for hormone receptor positive, HER2 positive breast cancer is chemotherapy and HER2 targeted therapy followed by endocrine therapy and surgery. The purpose of this Research Study is to see if taking endocrine the…
Sponsor: Legacy Health System
NCT ID: NCT07506876
Sites in Washington: - Legacy Salmon Creek Medical Center — Vancouver, Washington
Phase 2 Recruiting Academic/Other
This phase II clinical trial studies how well craniospinal irradiation (CSI) with hippocampal avoidance, using proton therapy or volumetric modulated arc therapy (VMAT), works in treating patients with breast cancer or non-small cell lung …
Sponsor: University of Washington
NCT ID: NCT06518057
Sites in Washington: - Fred Hutch/University of Washington Cancer Consortium — Seattle, Washington
Phase 2 Recruiting Academic/Other
This phase II trial tests the accuracy of functional imaging (FFNP)-positron emission tomography (PET)/computed tomography (CT) to predict response to abemaciclib plus endocrine therapy. Abemaciclib is a drug used to treat certain types of…
Sponsor: University of Washington
NCT ID: NCT06179303
Sites in Washington: - Fred Hutch/University of Washington Cancer Consortium — Seattle, Washington
Phase 1, Phase 2 Recruiting Academic/Other
This clinical trial studies how well fluorine F 18 fluorthanatrace (\[18F\]FTT) positron emission tomography (PET) works in imaging patients with breast cancer that has spread from where it first started (primary site) to other places in t…
Sponsor: University of Washington
NCT ID: NCT06502691
Sites in Washington: - Fred Hutch/University of Washington Cancer Consortium — Seattle, Washington
Phase 2 Recruiting Academic/Other
This phase II trial studies the immunologic response and side effects of using the WOKVAC vaccine in combination with chemotherapy and HER2-targeted monoclonal antibody therapy before surgery in treating patients with breast cancer. Vaccin…
Sponsor: University of Washington
NCT ID: NCT04329065
Sites in Washington: - Fred Hutch/University of Washington Cancer Consortium — Seattle, Washington
Phase 1 Recruiting Industry
This trial will look at a drug called sigvotatug vedotin (SGN-B6A) alone and with pembrolizumab, with or without chemotherapy, to find out whether it is safe for people who have solid tumors. It will study sigvotatug vedotin to find out wh…
Sponsor: Seagen, a wholly owned subsidiary of Pfizer
NCT ID: NCT04389632
Sites in Washington: - Northwest Medical Specialities. PLLC — Bonney Lake, Washington
- Swedish Cancer Institute - Edmonds Campus — Edmonds, Washington
- Swedish Cancer Institute Edmonds Campus — Edmonds, Washington
- Northwest Medical Specialities.PLLC — Federal Way, Washington
- Northwest Medical Specialities. PLLC — Gig Harbor, Washington
Phase 1 Recruiting Industry
This is a Phase 1b open-label, 2-part study in 3 treatment groups. The 3 treatment groups are as follows: Treatment Group 1: Palazestrant (OP-1250) in combination with ribociclib (KISQALI®, Novartis Pharmaceuticals Corporation). Treatment …
Sponsor: Olema Pharmaceuticals, Inc.
NCT ID: NCT05508906
Sites in Washington: - Northwest Medical Specialties — Tacoma, Washington
Phase 1 Recruiting Industry
The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of \[177Lu\]Lu-NNS309 and the safety and imaging properties of \[68Ga\]Ga-NNS309 in patients aged ≥ 18 years with locally advanced or met…
Sponsor: Novartis Pharmaceuticals
NCT ID: NCT06562192
Sites in Washington: - University Of Washington — Seattle, Washington